Dietary and pharmacological antioxidants in atherosclerosis

Current Opinion in Lipidology

Volumn 10, Issue 6, 1999, Pages 589-597

  Stocker, Roland ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; LOW DENSITY LIPOPROTEIN; POLYPHENOL DERIVATIVE; PROBUCOL;

ATHEROSCLEROSIS; DIET; DRUG MECHANISM; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; VITAMIN BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; ARTERIOSCLEROSIS; CORONARY DISEASE; DIET; HUMANS; LIPOPROTEINS, LDL;

ANIMALIA;

EID: 0033400906     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199912000-00014     Document Type: Review

References (100)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-924.
2. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The yin and yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16:831-842.
3. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337:408-416.
4. Heinecke JW. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1998; 141:1-15. •• An excellent review that evaluates and addresses the potential pathways that promote LDL oxidation in vivo, and the impact of antioxidants on atherogenesis in animals and its clinical implications.
5. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, et al. Probucol prevents the progression of atheroslcerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987; 84:5928-5931.
6. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987; 84:7725-7729.
7. Björkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L, Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 1991; 11:15-22.
8. Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA, et al. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N-diphenyl-phenylenediamine. J Clin Invest 1992; 89:1885-1891.
9. Gaziano JM. Antioxidants in cardiovascular disease: randomized trials. Nutrition 1996; 12:583-588.
10. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53:326S-334S.
11. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334:1156-1162.
12. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450-1456.
13. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328:1444-1449.
14. Willy C, Thiery J, Menger M, Messmer K, Arfors KE, Lehr HA. Impact of vitamin E supplement in standard laboratory animal diet on microvascular manifestation of ischemia/reperfusion injury. Free Radic Biol Med 1995; 19:919-926.
15. Rimm EB, Stampfer MJ. The role of antioxidants in preventive cardiology. Curr Opin Cardiol 1997; 12:188-194.
16. Faggiotto A, Poli A, Catapano AL. Antioxidants and coronary artery disease. Curr Opin Lipidol 1998; 9:541-549.
17. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354:447-455. •• The most recently published study from a prospective, placebo-controlled intervention trial with vitamin E. Compared with the CHAOS study [18] the GISSI trial involved a much larger number of subjects for a longer follow-up period, and there were no changes in the amount of vitamin E supplemented during the trial.
18. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-786.
19. The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029-1035.
20. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85:1483-1492.
21. Meydani SN, Meydani M, Blumberg JB, Leka LS, Pedrosa M, Diamond R, et al. Assessment of the safety of supplementation with different amounts of vitamin E in healthy older adults. Am J Clin Nutr 1998; 68:311-318. • This kind of double-blinded, placebo-controlled study needs to be carried for longer periods of time and with subject groups comparable to those enrolled in clinical intervention studies on the effects of vitamins on CHD.
22. Upston JM, Terentis AC, Stocker R. Tocopherol-mediated peroxidation (TMP) of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement. FASEB J 1999; 13:977-994. • A comprehensive review summarizing the features of lipid peroxidation and its inhibition by vitamin E in lipoproteins versus homogeneous systems. The study discusses whether lipid oxidation in the arterial wall is likely to occur in the presence or absence of vitamin E.
23. Chen L, Haught WH, Yang B, Saldeen TG, Parathasarathy S, Mehta JL. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 1997; 30:569-575.
24. Tijburg LB, Wiseman SA, Meijer GW, Weststrate JA. Effects of green tea, black tea and dietary lipophilic antioxidants on LDL oxidizability and atherosclerosis in hypercholesterolaemic rabbits. Atherosclerosis 1997; 135:37-47.
25. Stocker R. The ambivalence of vitamin E in atherogenesis. Trends in Biochemical Sciences 1999; 24:219-223. • A brief review highlighting the complexity of the role of vitamin E as an antioxidant for LDL and its effect on atherosclerosis.
26. Burton GW, Ingold KU. Vitamin E: application of the principles of physical organic chemistry to the exploration of its structure and function. Acc Chem Res 1986; 19:194-201.
27. Bowry VW, Stocker R. Tocopherol-mediated peroxidation. The pro-oxidant effect of vitamin E on the radical-initiated oxidation of human low-density lipoprotein. J Am Chem Soc 1993; 115:6029-6044.
28. Parker RA, Sabrah T, Cap M, Gill BT. Relation of vascular oxidative stress, α-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters. Arterioscler Thromb Vasc Biol 1995; 15:349-358.
29. Sulkin NM, Sulkin DF. Intimal lesions in arteries of vitamin E deficient rats. Proc Soc Exp Biol Med 1960; 103:111-115.
30. Xu R, Yokoyama WH, Irving D, Rein D, Walzern RL, German JB. Effect of dietary catechin and vitamin E on aortic fatty streak accumulation in hypercholesterolemic hamsters. Atherosclerosis 1998; 137:29-36.
31. Özer NK, Sirikci Ö, Taha S, San T, Moser U, Azzi A. Effect of vitamin E and probucol on dietary cholesterol-induced atherosclerosis in rabbits. Free Radic Biol Med 1998; 24:226-233.
32. Stein O, Dabach Y, Hollander G, Halperin G, Thiery J, Stein Y. Relative resistance of the hamster to aortic atherosclerosis in spite of prolonged vitamin E deficiency and dietary hypercholesterolemia. Putative effect of increased HDL? Biochim Biophys Acta 1996; 1299:216-222.
33. Wójcicki J, Rózewicka L, Barcew-Wiszniewska B, Samochowiec L, Juzwiak S, Kadlubowska D, et al. Effect of selenium and vitamin E on the development of experimental atherosclerosis in rabbits. Atherosclerosis 1991; 87:9-16.
34. Rózewicka L, Barcew-Wiszniewska B, Wójcicki J, Samochowiec L, Krasowska B. Protective effect of selenium and vitamin E against changes induced in heart vessels of rabbits fed chronically on a high-fat diet. Kitasato Arch Exp Med 1991; 64:183-192.
35. Schwenke DC, Behr SR. Vitamin E combined with selenium inhibits atherosclerosis in hypercholesterolemic rabbits independently of effects on plasma cholesterol concentrations. Circ Res 1998; 83:366-377. • A careful study suggesting that local differences in the anti-atherogenic efficacy of antioxidant treatment in rabbits may relate to differences in the endogenous tissue content vitamin E.
36. Weitzel G, Schön H, Gey F, Buddecke E. Fettlösliche Vitamine and Atherosklerose. Z Physiol Chem 1956; 304:247-272.
37. Brattsand R. Actions of vitamins A and E and some nicotinic acid derivatives on plasma lipids and on lipid infiltration of aorta in cholesterol-fed rabbits. Atherosclerosis 1975; 22:47-61.
38. Sun J, Giraud DW, Moxley RA, Driskell JA. β-Carotene and α-tocopherol inhibit the development of atherosclerotic lesions in hypercholesterolemic rabbits. Int J Vit Nutr Res 1997; 67:155-163.
39. Bocan TM, Mueller SB, Brown EQ, Uhlendorf PD, Mazur MJ, Newton RS. Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand white rabbits. Exp Mol Pathol 1992; 57:70-83.
40. Crawford RS, Kirk EA, Rosenfeld ME, LeBoeuf RC, Chait A. Dietary antioxidants inhibit development of fatty streak lesions in the LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18:1506-1513.
41. Morel DW, Llera-Moya M, Friday KE. Treatment of cholesterol-fed rabbits with dietary vitamins E and C inhibits lipoprotein oxidation but not development of atherosclerosis. J Nutr 1994; 124:2123-2130.
42. Sun YP, Zhu BQ, Sievers RE, Norkus EP, Parmley WW, Deedwania PC. Effects of antioxidant vitamins C and E on atherosclerosis in lipid-fed rabbits. Cardiology 1998; 89:189-194.
43. Shaish A, George J, Gilburd B, Keren P, Levkovitz H, Harats D. Dietary β-carotene and α-tocopherol combination does not inhibit atherogenesis in an ApoE-deficient mouse model. Arterioscler Thromb Vasc Biol 1999; 19:1470-1475. • This study suggests that moderate levels of β-carotene and α-tocopherol have no effect on atherogenesis in apolipoprotein E-deficient mice, a result that appears to be in contrast to the report of Pratico et al. [92**].
44. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci USA 1989; 86:6377-6381.
45. Lynch SM, Gaziano JM, Frei B. Ascorbic acid and atherosclerotic cardiovascular disease. Subcell Biochem 1996; 25:331-367.
46. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 1997; 17:2744-2752.
47. Wu YJ, Hong CY, Lin SJ, Wu P, Shiao MS. Increase of vitamin E content in LDL and reduction of atherosclerosis in cholesterol-fed rabbits by a water-soluble antioxidant-rich fraction of Salvia miltiorrhiza. Arterioscler Thromb Vasc Biol 1998; 18:481-486.
48. Aviram M, Fuhrman B. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis. Atherosclerosis 1998; 137 (Suppl.):S45-50.
49. Yamakoshi J, Kataoka S, Koga T, Ariga T. Proanthocyanidin-rich extract from grape seeds attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 1999; 142:139-149.
50. Leighton F, Cuevas A, Guasch V, Perez DD, Strobel P, San Martin A, et al. Plasma polyphenols and antioxidants, oxidative DNA damage and endothelial function in a diet and wine intervention study in humans. Drugs Exp Clin Res 1999; 25:133-141. • A careful and extensive study investigating the effects of moderate red wine consumption on biochemical, physiological, and clinical parameters related to atherosclerosis and other chronic diseases.
51. Tardif J-C, Côté G, Lespérance J, Bourassa M, Lambert J, Doucet S, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337:365-372.
52. Setsuda M, Inden M, Hiraoka N, Okamoto S, Tanaka H, Okinaka T, et al. Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clin Ther 1993; 15:374-382.
53. Lee YJ, Daida H, Yokoi H, Miyano H, Takaya J, Sakurai H, et al. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 1996; 37:327-332.
54. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996; 132:23-29.
55. Yokoi H, Daida H, Kuwabara Y, Hishikawa H, Takatsu F, Tomihara H, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the probucol angioplasty restenosis trial. J Am Coll Cardiol 1997; 30:855-862.
56. Rodes J, Cote G, Lesperance J, Bourassa MG, Doucet S, Bilodeau L, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 1998; 97:429-436. • This study provides evidence that probucol is also effective in preventing restenosis in small coronary arteries after balloon injury.
57. Cote G, Tardif JC, Lesperance J, Lambert J, Bourassa M, Bonan R, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation 1999; 99:30-35. • An interesting study addressing possible mechanisms of inhibitory action of probucol on restenosis in human coronary arteries.
58. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB, Ivanhoe R, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 1994; 331:1331-1337.
59. Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of restenosis by Elisor after transluminal coronary angioplasty. J Am Coll Cardiol 1997; 30:863-869.
60. Sekiya M, Funada J, Watanabe K, Miyagawa M, Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 1998; 82:144-147.
61. Ferns GAA, Forster L, Steward-Lee A, Konneh M, Nourooz-Zadeh J, Änggård EE. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci USA 1992; 89:11312-11316.
62. Schneider JE, Berk BC, Gravanis MB, Santoian EC, Cipolla GD, Tarazona N, et al. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation 1993; 88:628-637.
63. Sasahara M, Raines EW, Chait A, Carew TE, Steinberg D, Wahl PW, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994; 94:155-164.
64. Nagano Y, Nakamura T, Matsuzawa Y, Cho M, Ueda Y, Kita T. Probucol and atherosclerosis in the Watanabe heritable hyperlipedemic rabbit long-term antiatherogenic effect and effects on established plaques. Atheroslcerosis 1992; 92:131-140.
65. Kajinami K, Nishitsuji M, Takeda Y, Shimizu M, Koizumi J, Mabuchi H. Long-term probucol treatment results in regression of xanthomas, but in progression of coronary atherosclerosis in a heterozygous patient with familial hypercholesterolemia. Atherosclerosis 1996; 120:181-187.
66. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74:875-883.
67. Stein Y, Stein O, Delplanque B, Fesmire JD, Lee DM, Alaupovic P. Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels. Atherosclerosis 1989; 75:145-155.
68. Daugherty A, Zweifel BS, Schonfeld G. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits. Br J Pharmacol 1991; 103:1013-1018.
69. Kleinveld HA, Demacker PN, Stalenhoef AF. Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1994; 14:1386-1391.
70. Zhang SH, Reddick RL, Avdievich E, Surles LK, Jones RG, Reynolds JB, et al. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J Clin Invest 1997; 99:2858-2866.
71. Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E-deficient mice: possible mechanisms of action. Circulation 1999; 99:1733-1739.
72. Bird DA, Tangirala RK, Fruebis J, Steinberg D, Witztum JL, Palinski W. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor deficient mice. J Lipid Res 1998; 39:1079-1090. • The first study to demonstrate a pro-atherogenic effect of probucol in the aortic root of mice deficient in LDL receptor.
73. Benson GM, Schiffelers R, Nicols C, Latchman J, Vidgeon-Hart M, Toseland CDN, et al. Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficient mice. Atherosclerosis 1998; 141:237-247.
74. Cynshi O, Kawabe Y, Suzuki T, Takashima Y, Kaise H, Nakamura M, et al. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proc Natl Acad Sci USA 1998; 95:10123-10128. • A potentially important work describing, for the first time, the anti-atherogenic activity of a desk-top-designed radical scavenger with co-antioxidant activity. If these early results can be confirmed in other models, BO-653 has the potential to be developed into a drug.
75. Mao SJ, Yates MT, Rechtin AE, Jackson RL, Van-Sickle WA. Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. J Med Chem 1991; 34:298-302.
76. Mao SJ, Yates MT, Parker RA, Chi EM, Jackson RL. Attenuation of atherosclerosis in a modified strain of hypercholesterolemic Watanabe rabbits with use of a probucol analogue (MDL 29,311) that does not lower serum cholesterol. Arterioscler Thromb 1991; 11:1266-1275.
77. Fruebis J, Steinberg D, Dresel HA, Carew TA. A comparison of the antiatherogenic effects of probucol and a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits. J Clin Invest 1994; 94:392-398.
78. Witting PK, Pettersson K, Östlund-Lindqvist A-M, Westerlund C, Wågberg M, Stocker R. Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 1999; 104:213-220. •• Using direct biochemical approaches, this study measures lipoprotein oxidation within the vessel wall of rabbits and compares the extent of inhibition of aortic lipid oxidation by probucol and a natural metabolite of it, with the effect of the drug on atherosclerosis. The study, for the first time, reports that the inhibition of aortic lipoprotein oxidation does not result in the inhibition of atherosclerosis.
79. Barnhart RL, Busch SJ, Jackson RL. Concentration-dependent antioxidant activity of probucol in low density lipoproteins in vitro: probucol degradation precedes lipoprotein oxidation. J Lipid Res 1989; 30:1703-1710.
80. Noguchi N, Iwaki Y, Takahashi M, Komuro E, Kato Y, Tamura K, et al. 2,3-Dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: design and evaluation as a novel radical-scavenging antioxidant against lipid peroxidation. Arch Biochem Biophys 1997; 342:236-243.
81. Shaish A, Daugherty A, O'Sullivan F, Schonfeld G, Heinecke JW. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J Clin Invest 1995; 96:2075-2082.
82. Fruebis J, Bird DA, Pattison J, Palinski W. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants. J Lipid Res 1997; 38:2455-2464.
83. Stocker R. Antioxidant defenses in the vascular wall. In: Oxidative stress and vascular disease. Keaney JF Jr (editor). Boston: Kluwer Academic Publishers; 1999: in press. • This review article summarizes the present knowledge on non-enzymatic and enzymatic antioxidants in the walls of vessels affected by atherosclerosis.
84. Suarna C, Dean RT, May J, Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of α-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 1995; 15:1616-1624.
85. Letters JM, Christison JK, Witting PK, Westin Eriksson A, Pettersson K, Stocker R. Changes to lipids and antioxidants in plasma and aortae of apoE-deficient mice. J Lipid Res 1999; 40:1104-1112. • A descriptive study reporting on the biochemical changes in the aorta of apolipoprotein E-deficient mice, suggesting that the content of oxidized lipids and antioxidants, including vitamin E, increase in parallel with an increasing duration of high fat feeding.
86. Niu X, Zammit V, Upston JM, Dean RT, Stocker R. Co-existence of oxidized lipids and a-tocopherol in all lipoprotein fractions isolated from advanced human atherosclerotic plaques. Arterioscl Thromb Vasc Biol 1999; 19:1708-1718. • A biochemical study indicating that comparable amounts of oxidized lipids and vitamin E are present in all lipoprotein classes present in advanced human lesions, suggesting that oxidative damage of lipoproteins in the arterial wall is not limited to LDL.
87. Witting PK, Pettersson K, Östlund-Lindqvist A-M, Westerlund C, Westin Eriksson A, Stocker R. Inhibition by a co-antioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice. FASEB J 1999; 13:667-675. •• The novel aspect of this study is the use of a synthetic radical scavenger that is kinetically inferior to vitamin E, yet effectively prevents lipid peroxidation and atherosclerosis in the aortas of mice.
88. Sattler W, Christison JK, Stocker R. Cholesterylester hydroperoxide reducing activity associated with isolated high- and low-density lipoproteins. Free Radic Biol Med 1995; 18:421-429.
89. Garner B, Waldeck AR, Witting PK, Rye K-A, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of HDL lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998; 273:6088-6095. • This mechanistic study addresses how lipoprotein-associated lipid hydroperoxides become chemically reduced to their corresponding alcohols.
90. Mashima R, Yamamoto Y, Yoshimura S. Reduction of phosphatidylcholine hydroperoxide by apolipoprotein A-I: purification of the hydroperoxide-reducing proteins from human blood plasma. J Lipid Res 1998; 39:1133-1140.
91. Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 1992; 13:341-390.
92. Pratico D, Tangirala RK, Radar D, Rokach J, FitzGerald GA. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice. Nature Med 1998; 4:1189-1192. •• A fascinating report linking an anti-atherogenic effect of vitamin E to the inhibition of lipid peroxidation in vivo. It will be important to confirm these findings in the future and to relate the concentration of the form of oxidized arachidonic acid measured directly to arachidonic acid.
93. Ylä-Herttuala S, Luoma J, Viita H, Hiltunen T, Sisto T, Nikkari T. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. J Clin Invest 1995; 95:2692-2698.
94. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999; 103:1597-1604. •• This elegant study indicates a role for 12/15-lipoxygenase in the pathogenesis of atherosclerosis, and suggests that inhibition of this enzyme may decrease disease progression.
95. Aratani Y, Koyama H, Nyui S, Suzuki K, Kura F, Maeda N. Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase. Infect Immun 1999; 67:1828-1836. • The generation of mice deficient in myeloperoxidase will allow direct examination of this pro-oxidant enzyme on atherogenesis.
96. Lake-Bruse KD, Faraci FM, Shesely EG, Maeda N, Sigmund CD, Heistad DD. Gene transfer of endothelial nitric oxide synthase (eNOS) in eNOS-deficient mice. Am J Physiol 1999; 277:H770-H776.
97. Tribble DL, Gong EL, Leeuwenburgh C, Heinecke JW, Carlson EL, Verstuyft JG, Epstein CJ. Fatty streak formation in fat-fed mice expressing human copper-zinc superoxide dismutase. Arterioscler Thromb Vasc Biol 1997; 17:1734-1740. This study shows that over-expressing CuZn-superoxide dismutase in the aorta of fat-fed atherosclerosis-susceptible mice does not result in an anti-atherogenic effect, raising the possibility that high tissue superoxide dismutase activity may potentiate atherogenesis.
98. de Haan JB, Bladier C, Griffiths P, Kelner M, O'Shea RD, Cheung NS, et al. Mice with a homozygous null mutation for the most abundant glutathione peroxidase, Gpx1, show increased susceptibility to the oxidative stress-induced agents paraquat and hydrogen peroxide. J Biol Chem 1998; 273:22528-22536.
99. Heinecke JW. Is lipid peroxidation relevant to atherogenesis? [commentary]. J Clin Invest 1999; 104:135-136. • In this commentary, Jay Heinecke asks pertinent questions related to the oxidation theory of atherosclerosis and how some of these can be addressed experimentally.
100. Offermann MK, Medford RM. Antioxidants and atherosclerosis: a molecular perspective. Heart Dis Stroke 1994; 3:52-57.